1.17
+0.055(+4.96%)
Currency In USD
| Previous Close | 1.11 |
| Open | 1.13 |
| Day High | 1.18 |
| Day Low | 1.12 |
| 52-Week High | 27.35 |
| 52-Week Low | 0.79 |
| Volume | 126,737 |
| Average Volume | 3.69M |
| Market Cap | 153.79M |
| PE | -0.43 |
| EPS | -2.71 |
| Moving Average 50 Days | 1.22 |
| Moving Average 200 Days | 2.76 |
| Change | 0.06 |
If you invested $1000 in RAPT Therapeutics, Inc. (RAPT) since IPO date, it would be worth $85.38 as of February 05, 2025 at a share price of $1.11. Whereas If you bought $1000 worth of RAPT Therapeutics, Inc. (RAPT) shares 5 years ago, it would be worth $34.69 as of February 05, 2025 at a share price of $1.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 09, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
GlobeNewswire Inc.
Jan 06, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients
RAPT Therapeutics Announces $150 Million Private Placement
GlobeNewswire Inc.
Dec 23, 2024 12:10 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with